- Home
- CPIX vs MRSN Comparison
CPIX vs MRSN Comparison
Compare CPIX & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPIX
- MRSN
- Stock Information
- Founded
- CPIX 1999
- MRSN 2001
- Country
- CPIX United States
- MRSN United States
- Employees
- CPIX N/A
- MRSN N/A
- Industry
- CPIX Biotechnology: Pharmaceutical Preparations
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CPIX Health Care
- MRSN Health Care
- Exchange
- CPIX Nasdaq
- MRSN Nasdaq
- Market Cap
- CPIX 68.7M
- MRSN 71.9M
- IPO Year
- CPIX 2009
- MRSN 2017
- Fundamental
- Price
- CPIX $4.22
- MRSN $0.34
- Analyst Decision
- CPIX
- MRSN Buy
- Analyst Count
- CPIX 0
- MRSN 3
- Target Price
- CPIX N/A
- MRSN $4.00
- AVG Volume (30 Days)
- CPIX 131.8K
- MRSN 3.1M
- Earning Date
- CPIX 03-04-2025
- MRSN 03-03-2025
- Dividend Yield
- CPIX N/A
- MRSN N/A
- EPS Growth
- CPIX N/A
- MRSN N/A
- EPS
- CPIX N/A
- MRSN N/A
- Revenue
- CPIX $37,867,945.00
- MRSN $40,497,000.00
- Revenue This Year
- CPIX N/A
- MRSN N/A
- Revenue Next Year
- CPIX N/A
- MRSN N/A
- P/E Ratio
- CPIX N/A
- MRSN N/A
- Revenue Growth
- CPIX N/A
- MRSN 9.88
- 52 Week Low
- CPIX $1.04
- MRSN $0.34
- 52 Week High
- CPIX $7.25
- MRSN $4.64
- Technical
- Relative Strength Index (RSI)
- CPIX 43.04
- MRSN 29.11
- Support Level
- CPIX $3.91
- MRSN $0.41
- Resistance Level
- CPIX $4.47
- MRSN $0.42
- Average True Range (ATR)
- CPIX 0.36
- MRSN 0.04
- MACD
- CPIX -0.17
- MRSN -0.00
- Stochastic Oscillator
- CPIX 23.37
- MRSN 3.43
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.